Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. (Q39831242)

15 September 2017

Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. (English)

1 reference

15 September 2017

1 reference

1 reference

1 reference

8

Kelly K Hunt

1 reference

15 September 2017

Markus Wagner

1

1 reference

15 September 2017

Vincent Roh

2

1 reference

15 September 2017

Michael Strehlen

3

1 reference

15 September 2017

Alexander Laemmle

4

1 reference

15 September 2017

Deborah Stroka

5

1 reference

15 September 2017

Bernhard Egger

6

1 reference

15 September 2017

Markus Trochsler

7

1 reference

15 September 2017

Daniel Candinas

9

1 reference

15 September 2017

Stephan A Vorburger

10

1 reference

15 September 2017

30 June 2009

1 reference

Journal of Gastrointestinal Surgery

15 September 2017

1 reference

15 September 2017

13

1 reference

15 September 2017

10

1 reference

15 September 2017

1781-1790

1 reference

https://scigraph.springernature.com/pub.10.1007/s11605-009-0948-x

15 September 2017

0 references

cites work

Cancer statistics, 2003.

1 reference

12 December 2020

Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail

1 reference

12 December 2020

Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer

1 reference

12 December 2020

Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine)

1 reference

12 December 2020

Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host

1 reference

12 December 2020

Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early allograft vasculopathy

1 reference

12 December 2020

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

1 reference

12 December 2020

Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization

1 reference

12 December 2020

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

1 reference

12 December 2020

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy

1 reference

12 December 2020

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

1 reference

12 December 2020

Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer

1 reference

12 December 2020

High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer

1 reference

12 December 2020

Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation.

1 reference

12 December 2020

Rapamycin: an anti-cancer immunosuppressant?

1 reference

12 December 2020

Novel functions of TIMPs in cell signaling

1 reference

12 December 2020

Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells

1 reference

12 December 2020

Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer

1 reference

12 December 2020

Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications.

1 reference

12 December 2020

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

12 December 2020

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

1 reference

12 December 2020

Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia

1 reference

12 December 2020

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

1 reference

12 December 2020

Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells

1 reference

12 December 2020

Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer

1 reference

12 December 2020

Review article: colorectal cancer chemotherapy

1 reference

12 December 2020

Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.

1 reference

12 December 2020

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

12 December 2020

Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro

1 reference

12 December 2020

Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line

1 reference

12 December 2020

K562 cells produce and respond to human erythroid-potentiating activity

1 reference

12 December 2020

Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer

1 reference

12 December 2020

Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis

1 reference

12 December 2020

NCCN Task Force Report: mTOR inhibition in solid tumors.

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.

1 reference

12 December 2020

10.1007/S11605-009-0948-X

Identifiers

DOI

1 reference

15 September 2017

1 reference